|
?:authorAffiliation
|
-
[\'Frank H. Netter M.D. School of Medicine at Quinnipiac University, North Haven, Connecticut, USA.\', \'Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, USA.\', \'Department of Medicine, Stem Cell Transplant and Cell Therapy Unit, IMIB-Arrixaca, Virgen De La Arrixaca University Hospital, University of Murcia, Murcia, Spain.\', \'Department of Biomedical Sciences, Humanitas University, Rozzano-Milano, Italy.\', \'Department of Oncology and Hematology, IRCCS - Humanitas Research Hospital, Rozzano-Milano, Italy.\', \'Intensive Care Unit, Virgen De La Arrixaca University Hospital, University of Murcia, Murcia, Spain.\', \'Josep Carreras Leukaemia Research Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain.\', \'Barcelona Endothelium Team, Barcelona, Spain.\', \'Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women\'s Hospital, Harvard Medical School, Boston, Massachusetts, USA.\', \'Department of Pediatrics, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI, USA.\', \'Department of Internal Medicine, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan, USA.\', \'Department of Molecular Pharmacology and Therapeutics, Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Chicago, Illinois, USA.\', \'Technion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.\', \'Techitra S.r.l., Milan, Italy.\', \'Hematopathology, Pathology Department, CDB, Hospital Clinic, Barcelona, Spain.\', \'IDIBAPS, Barcelona, Spain.\', \'Division of Hematologic Malignancy, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}